Deep learning-based detection of cerebral microbleeds on 2D T2*-weighted GRE MRI: toward ARIA-H risk assessment in

Soo-Oh Yang1, Jehyun Ahn2, Young Hee Jung3

  • 1BeauBrain Healthcare, Inc., Seoul, Republic of Korea.

Abstract

Insights

An AI model accurately detects cerebral microbleeds (CMBs) on 2D GRE MRI, aiding Alzheimer's disease treatment safety. This automated system helps identify patients at risk for ARIA-H, improving safety monitoring.

Area of Science:

  • Neuroimaging
  • Artificial Intelligence
  • Alzheimer's Disease Research

Background:

  • Amyloid-related imaging abnormalities with hemorrhage (ARIA-H) are a critical safety concern in Alzheimer's disease anti-amyloid therapies.
  • Cerebral microbleeds (CMBs) are radiologically indistinguishable from ARIA-H, necessitating accurate detection for treatment eligibility and safety monitoring.
  • Manual identification of CMBs on 2D T2*-weighted GRE MRI is time-consuming and prone to variability.

Purpose of the Study:

  • To develop and validate an AI-based model for automated CMB detection using standard 2D T2*-weighted GRE MRI.
  • To provide a tool for efficient and reliable CMB assessment in clinical settings.

Main Methods:

  • Implementation of a YOLOv11 deep learning model integrated with a novel multi-channel preprocessing pipeline to enhance CMB visibility.
  • Training and testing the model on a dataset of 758 participants, with expert consensus serving as the ground truth.
  • Utilizing an optimized basic preprocessing with super-resolution (BP+SR) pipeline.

Main Results:

  • The AI model achieved a lesion-level sensitivity of 0.694, precision of 0.705, and F1-score of 0.699.
  • Patient-level analysis for elevated CMB burden (≥4) demonstrated high performance with 0.933 sensitivity and 0.935 specificity.
  • Regional analysis showed sensitivity of 0.625 for lobar CMBs and 0.627 for deep CMBs.

Conclusions:

  • The study confirms the feasibility of robust CMB detection using only 2D T2*-weighted GRE MRI.
  • The AI system is proposed as a decision-support tool for GRE-based CMB screening and ARIA-H risk stratification.
  • Final ARIA grading and clinical decisions necessitate expert neuroradiological confirmation.

Related Concept Videos